Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
The tumour microenvironment (TME) has a major role in chemoresistance in multiple myeloma. The authors show that a nanoparticle targeted to TME and loaded with bortezomib (BTZ) and Y27632 is more effective than free drugs, non-targeted and single-agent controls and reduces BTZ-related side effects.
Saved in:
Main Authors: | Cinzia Federico, Kinan Alhallak, Jennifer Sun, Kathleen Duncan, Feda Azab, Gail P. Sudlow, Pilar de la Puente, Barbara Muz, Vaishali Kapoor, Luna Zhang, Fangzheng Yuan, Matea Markovic, Joseph Kotsybar, Katherine Wasden, Nicole Guenthner, Shannon Gurley, Justin King, Daniel Kohnen, Noha N. Salama, Dinesh Thotala, Dennis E. Hallahan, Ravi Vij, John F. DiPersio, Samuel Achilefu, Abdel Kareem Azab |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/ec116aa5de4e46b1b6f2162c28d0c689 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
by: Kinan Alhallak, et al.
Published: (2021) -
Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
by: Michele Tanturli, et al.
Published: (2011) -
Bortezomib in autoimmune hemolytic anemia and beyond
by: Raffaella Pasquale, et al.
Published: (2021) -
Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells
by: Shu Wang, et al.
Published: (2017) -
Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
by: A. Malacrida, et al.
Published: (2021)